Delfini Evidence-based Medicine Logo

Flowing Evidence into Cost Analysis: Powerful Ways with NNT

Analysis Example: Discussion follows the analysis example.
Fictional Scenario is repeated below the discussion.
EBM Cost Analysis Help


Resources:
On The Same Page™
 .......
Home
What's New
Intro Links
Services
Resources
Success Stories
Notices
About Us
About Our Work
Testimonials
Other
Site Navigator
Contact Us

Site Search
.......
delfini.org
Delfini Group EBM Dolphin

Also creators of
medicalleaders.org

Quick Navigator to Selected Resources:

Discussion

In our fictional scenario, by switching from our current care to our new drug, we will have done the following:

  • Significantly reduced quality of care. We will now prevent roughly 80 hip fractures compared to roughly 138 prevented with current treatment in a course of 14.5 years.
  • Significantly increased our expenses. We will now have spent $3.6MM less in prevention treatment, but will have significant new expenses due to the increase in hip fractures.

This examples shows several things:

  1. You can do a simple, yet powerful "back-of-the-envelope" analysis using a spreadsheet tool.
  2. You need to look at prevalence data in your population, consider what you are currently doing, assess the evidence and then do sensitivity analyses to explore potential impacts of practice change.
  3. Flowing evidence into your cost analysis is highly important and revealing. In this instance we see that even though a new drug may be less expense per year of treatment, we are actually significantly reducing our quality of care AND increasing our expenses by making a switch.

    4. To compute a cost per benefit, which you can then use for comparison purposes:

    Quick Equation #1: NNT x study period x dollars per time unit

    OR #2: NNT x study period cost

  4. Many times people talk about NNT without including the appropriate associated time period. We see by this example, that it is this difference in time periods between the old agent and the new that has made the significant difference.

Fictional Scenario
Lifetime risk of hip fracture in women is 15% with significant mortality (20-30% of women die in the first year following hip fracture).


HRT is now found to have many risks. Other fracture prevention drugs have risks. There is a new (fictional) drug on the market that has fewer risks and that many docs are starting to use on high and moderate risk women. The drug is getting a lot of press attention and has good evidence behind it.


Many women in your organization are requesting information and treatment for prevention of fractures. Many are asking about this new drug.


One year of treatment is cheaper than alendronate.
Delfini SERVICES
We offer a wide range of supportive services with the ultimate goal of increasing health care organizations’ and clinicians’ abilities to provide high quality, evidence-based care and to improve medical decision-making for organizations, leaders, teams, clinicians and patients.
Delfini About Our Work Delfini Group EBM DolphinDelfini Group EBM Dolphin
Resources at —

Return to Top

© Delfini Group, LLC, 2002-2010. All Rights Reserved Worldwide.
Use of this website implies your agreement to our Notices.

EBM Solutions for Evidence Based Health Care Quality